Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04671251
• Other study ID #: AEVI-007-MM-101
• Status: Completed
• Phase: Phase 1
• Start date: December 15, 2020
• Est. completion date: March 30, 2022

Study information

• Verified date: February 2024
• Source: Avalo Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma. The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.

Description:

This was a multicenter, open-label, dose-escalation, sequential groups Phase 1b clinical study in subjects with R/R multiple myeloma. The study utilized a "3+3" design. Three subjects were enrolled at each dose, starting with the initial dose of 4 mg/kg. If there were no DLTs, escalation to the next cohort took place. If there was 1 DLT, then the cohort was to be expanded to 6. If there were no further DLTs, then escalation to the next dose took place. If there were 2 DLTs in the initial 3 subjects, or 2 in the expanded cohort of 6 subjects, then the maximally tolerated dose (MTD) had been exceeded and dose escalation stopped. The dose prior to the dose where DLT was observed was then the RP2D. To allow safety assessment, the dosing of subjects within each dose level was staggered, with at least 24 hours between each subject.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: March 30, 2022
• Est. primary completion date: March 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject has active R/R multiple myeloma.

2. Subject has measurable myeloma based on any of the following:

• Serum M-protein > 0.5 g/dL
• Urine M-protein > 200 mg/24 hours
• Serum free light chains > 10 mg/dL
• Measurable plasmacytoma or extramedullary disease

3. Subject has active myeloma despite prior therapy with a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. Note: Subject must not be a candidate for regimens known to provide clinical benefit.

4. Subject has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.

5. Subject is > 18 years of age.

6. Subject has adequate hematopoietic, renal and hepatic function, defined as:

• Absolute neutrophil count > 1,000/µL; platelet count > 75,000/µL in patients with < 50% marrow involvement
• Absolute neutrophil count > 750/µL; platelet count > 50,000/µL in patients with >50% marrow involvement
• Serum creatinine < 2.5 mg/dL or calculated creatinine clearance of > 30 mL/min according to the Cockcroft-Gault equation
• Aspartate transaminase/alanine transaminase =2.5× the upper limit of normal (ULN) and total bilirubin < 2× the ULN

7. If applicable, the subject has undergone prior autologous hematopoietic stem cell transplantation more than 100 days prior to the Screening Visit.

8. Female patients of childbearing potential who are heterosexually active and male patients with female sexual partners of childbearing potential must agree to use an effective method of contraception (eg, oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device) or abstain from sexual activity during the study and for 220 days (5 half-lives) following the last dose of study medication, or to abstain from sexual intercourse for this duration of study participation. A woman not of childbearing potential is one who has undergone bilateral oophorectomies or who is post-menopausal, defined as the absence of menstrual periods for 12 consecutive months.

9. Subject has provided written informed consent for this study.

Exclusion Criteria:

1. Subject has currently active infection requiring use of systemic antimicrobial therapy.

2. Subject has received corticosteroids (>10 mg/daily prednisone or equivalent) or chemotherapy within 2 weeks of study drugs (4 weeks for nitrosourea, melphalan or monoclonal antibodies).

3. Subject has hyperviscosity syndrome.

4. Subject has central nervous system involvement by myeloma, including leptomeningeal involvement.

5. Subject is judged to be at risk for impending fracture.

6. Subject has known amyloidosis or POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) syndrome.

7. Subject had another malignancy within 1 year of study entry with high probability of recurrence.

8. Subject is pregnant or lactating.

9. Subject has a history of, or tests positive for, hepatitis B, untreated hepatitis C or human immunodeficiency virus (HIV). Subject with hepatitis C who has received a full course of anti-viral therapy or who is currently receiving anti-viral therapy with undetectable levels of hepatitis C RNA is eligible for the trial.

10. Subject has undergone major surgery or trauma within 4 weeks of study entry.

11. Subject has been previously treated with an anti IL 18 antibody.

12. Subject is currently taking immunomodulatory drugs, including pharmacologic doses of systemic glucocorticoids (> 10 mg prednisone daily or equivalent), anti tumor necrosis factor alpha (TNFa) antibodies, anti-IL-17 antibodies, anti IL 12/23 antibodies, phosphodiesterase-4 (PDE-4) inhibitors, janus kinase (JAK) inhibitors, IL-6 inhibitors, rituximab, methotrexate, cyclosporine, mycophenolate.

13. Subject with known active autoimmune disorders including, but not limited to, rheumatoid arthritis, lupus, systemic sclerosis, Sjogren's syndrome, psoriatic arthritis, ulcerative colitis, Crohn's disease, vasculitis, multiple sclerosis. Subjects with autoimmune endocrinopathies on stable doses of replacement hormone therapy are eligible for the trial.

14. Subject has had a prior allogeneic transplant.

15. Subject has New York Heart Association (NYHA) Class III or IV Congestive Heart Failure (CHF), myocardial infarction or acute coronary syndrome within 6 months prior to the Screening Visit, ongoing angina pectoris, severe peripheral vascular disease, or any other concomitant medical disorder that might interfere with the subject's participation in the trial or interpretation of the study data.

16. Subject has psychiatric, substance abuse or social conditions that would interfere with the subject's participation or cooperation with the requirements of the trial.

17. Subject has known hypersensitivity to any of the components of AEVI-007.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• AEVI-007
50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.

Locations

Country	Name	City	State
United States	American Oncology Partners of Maryland, PA	Bethesda	Maryland
United States	Levine Cancer Institute	Charlotte	North Carolina
United States	Florida Cancer Specialists	Lake Mary	Florida
United States	Froedtert Hospital & the Medical College of Wisconsin	Milwaukee	Wisconsin
United States	University of California, Davis Comprehensive Cancer Center	Sacramento	California
United States	Florida Cancer Specialists	Sarasota	Florida
United States	James R. Berenson, MD., Inc.	West Hollywood	California

Sponsors (1)

Lead Sponsor	Collaborator
Avalo Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recommended Phase 2 Dose	Identify the recommended Phase 2 dose based on safety, pharmacokinetics and pharmacodynamics observed in this Phase 1b study.	Cohorts 1-3 will take approximately 4-5 months
Secondary	Incidence of Treatment Emergent Adverse Events (TEAEs)		Approximately 9 months
Secondary	Incidence of Clinically Significant Changes in Clinical Laboratory Results		Approximately 9 months
Secondary	Incidence of Clinically Significant Changes in Vital Signs		Approximately 9 months
Secondary	Incidence of Clinically Significant Changes in Electrocardiogram Recordings		Approximately 9 months
Secondary	Incidence of Clinically Significant Changes to Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score		Approximately 9 months
Secondary	Incidence of Clinically Significant Changes in Physical Examination Findings		Approximately 9 months
Secondary	Maximum Observed Concentration of AEVI-007		Approximately 9 months
Secondary	Apparent Terminal Half-Life of AEVI-007		Approximately 9 months
Secondary	Clearance of AEVI-007		Approximately 9 months
Secondary	Volume of Distribution of AEVI-007		Approximately 9 months
Secondary	Area Under the Concentration-Time Curve From Time 0 to Time t of AEVI-007		Approximately 9 months
Secondary	Anti-myeloma activity	To assess the anti-myeloma activity of AEVI-007 based on International Myeloma Working Group (IMWG) criteria for response	Approximately 9 months
Secondary	Determination of ADAs	To determine the incidence of anti-drug antibodies to AEVI-007.	Approximately 9 months
Secondary	Time to Response (TTR)	Defined as the time from start of the treatment to the first observation of PR or better. TTR is restricted to only subjects with confirmed responses.	Approximately 9 months
Secondary	Progression Free Survival (PFS)	Defined as the duration from start of the treatment to disease progression or death (regardless of cause of death), whichever comes first	Approximately 9 months
Secondary	Duration of Response	Defined as the duration from the first observation of PR to the time of disease progression, with deaths from causes other than progression censored	Approximately 9 months